Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids.

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,240 · see citing works

Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction

Chomczyński, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 47,092 · see citing works

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224 · see citing works

OSTEOBLASTIC CELLS ARE INVOLVED IN OSTEOCLAST FORMATION

Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., & Suda, T. (1988) · Endocrinology · doi:10.1210/endo-123-5-2600 · Cited by 934 · see citing works

Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.

Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787 · see citing works

Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis.

CANALIS, E. M. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.10.8855781 · Cited by 441 · see citing works

Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors

Udagawa, N., Takahashi, N., Katagiri, T., Tamura, T., Wada, S., Findlay, D., Martin, T., Hirota, H., Taga, T., Kishimoto, T., et al. (1995) · Journal of Experimental Medicine · doi:10.1084/jem.182.5.1461 · Cited by 415 · see citing works

Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact.

Jimi, E., Nakamura, I., Amano, H., Taguchi, Y., Tsurukai, T., Tamura, M., Takahashi, N., & Suda, T. (1996) · Endocrinology · doi:10.1210/endo.137.8.8754795 · Cited by 198 · see citing works

Glucocorticoids inhibit bone resorption by isolated rat osteoclasts by enhancing apoptosis

Dempster, D., Moonga, B., Stein, L., Horbert, W., & Antakly, T. (1997) · Journal of Endocrinology · doi:10.1677/joe.0.1540397 · Cited by 180 · see citing works

Mechanisms by which cells of the osteoblast lineage control osteoclast formation and activity

Martin, T. J., & Ng, K. W. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240560312 · Cited by 173 · see citing works

Mechanisms of glucocorticoid action in bone cells

Delany, A. M., Dong, Y., & CANALIS, E. M. (1994) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240560304 · Cited by 133 · see citing works

Role of vitamin D in bone resorption

Suda, T., Takahashi, N., & Abe, E. (1992) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240490110 · Cited by 97 · see citing works

Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: Role of cAMP-dependent protein kinase

Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M., & Chihara, K. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110110 · Cited by 97 · see citing works

Glucocorticoids Impair Bone Resorptive Activity and Viability of Osteoclasts Disaggregated from Neonatal Rat Long Bones*

Tobias, J. H., & Chambers, T. J. (1989) · Endocrinology · doi:10.1210/endo-125-3-1290 · Cited by 90 · see citing works

Dexamethasone Stimulates Osteoclast-like Cell Formation by Directly Acting on Hemopoietic Blast Cells and Enhances Osteoclast-like Cell Formation Stimulated by Parathyroid Hormone and Prostaglandin E2

Kaji, H., Sugimoto, T., Kanatani, M., Nishiyama, K., & Chihara, K. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.5.734 · Cited by 85 · see citing works

Expression of functional growth hormone receptors in cultured human osteoblast-like cells

Nilsson, A., Swolin‐Eide, D., Enerbäck, S., & Ohlsson, C. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530587 · Cited by 82 · see citing works

Tumor necrosis factors α and β can stimulate bone resorption in cultured mouse calvariae by a Prostaglandin-independent mechanism

Lerner, U. H., & Ohlin, A. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080205 · Cited by 71 · see citing works

Steroid-Induced Osteoporosis

Bockman, R. S., & Weinerman, S. A. (1990) · Orthopedic Clinics of North America · doi:10.1016/s0030-5898(20)31568-6 · Cited by 61 · see citing works

Erratum: Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact (Endocrinology 137 (2187-2190))

Jimi, E., Nakamura, I., Amano, H., Taguchi, Y., Tsurukai, T., Tamura, M., Takahashi, N., & Suda, T. (1996) · Cited by 54 · see citing works

Dexamethasone suppresses in vivo levels of bone collagen synthesis in neonatal mice

Advani, S., Lafrancis, D., Bogdanovic, E., Taxel, P., Raisz, L. G., & Kream, B. E. (1997) · Bone · doi:10.1016/s8756-3282(96)00314-6 · Cited by 50 · see citing works

Effects of deflazacort on aspects of bone formation in cultures of intact calvariae and osteoblast-enriched cells

CANALIS, E. M., & Avioli, L. V. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070912 · Cited by 44 · see citing works

Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone

Conaway, H. H., Grigorie, D., & Lerner, U. H. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111008 · Cited by 42 · see citing works

Are osteoblastic cells required for the control of osteoclast activity by parathyroid hormone?

Jilka, R. L. (1986) · PubMed · Cited by 32 · see citing works

Transforming growth factor-β stimulates bone resorption in neonatal mouse calvariae by a prostaglandin-unrelated but cell proliferation-dependent pathway

Lerner, U. H. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111106 · Cited by 26 · see citing works

Serum blocks the osteolytic effect of cortisol in neonatal mouse calvaria

Lowe, C., Gray, D. H., & Reid, I. R. (1992) · Calcified Tissue International · doi:10.1007/bf00298799 · Cited by 22 · see citing works

Intercellular chatter: osteoblasts, osteoclasts and interleukin 6

Hofbauer, L. C., & Heufelder, A. E. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340425 · Cited by 15 · see citing works

The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption

Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,167 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

RANK-L and RANK: T Cells, Bone Loss, and Mammalian Evolution

Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064753 · Cited by 817 · see citing works

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling

Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663 · see citing works

Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells

Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., & Khosla, S. (1999) · Bone · doi:10.1016/s8756-3282(99)00162-3 · Cited by 630 · see citing works

Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology

Hofbauer, L. C., & Heufelder, A. E. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100226 · Cited by 586 · see citing works

The Role of Liver-Derived Insulin-Like Growth Factor-I

Ohlsson, C., Mohan, S., Sjögren, K., Tivesten, Å., Isgaard, J., Isaksson, O. G. P., Jansson, J., & Svensson, J. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0010 · Cited by 448 · see citing works

RANK/RANKL: Regulators of Immune Responses and Bone Physiology

Leibbrandt, A., & Penninger, J. M. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.016 · Cited by 420 · see citing works

RANK Ligand and Osteoprotegerin

Schoppet, M., Preissner, K. T., & Hofbauer, L. C. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000012303.37971.da · Cited by 403 · see citing works

Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.

Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391 · see citing works

Extraintestinal manifestations in inflammatory bowel disease

Danese, S. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i46.7227 · Cited by 373 · see citing works

Epicardial-Derived Cell Epithelial-to-Mesenchymal Transition and Fate Specification Require PDGF Receptor Signaling

Smith, C. L., Baek, S. T., Sung, C. Y., & Tallquist, M. D. (2011) · Circulation Research · doi:10.1161/circresaha.110.235531 · Cited by 339 · see citing works

MLO-Y4 Osteocyte-Like Cells Support Osteoclast Formation and Activation

Zhao, S., Kato, Y., Zhang, Y., Harris, S., Ahuja, S. S., & Bonewald, L. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.11.2068 · Cited by 322 · see citing works

Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy

Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258 · see citing works

The OPG/RANKL/RANK system in metabolic bone diseases.

Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 254 · see citing works

Glucocorticoid Receptor-Dependent Gene Regulatory Networks

Le, P. P., Friedman, J. R., Schug, J., Brestelli, J. E., Parker, J. B., Bochkis, I. M., & Kaestner, K. H. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010016 · Cited by 250 · see citing works

RANKL Expression Is Related to the Differentiation State of Human Osteoblasts

Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245 · see citing works

Role of RANKL and RANK in bone loss and arthritis

Jones, D. H., Kong, Y.-Y., & Penninger, J. M. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii32 · Cited by 222 · see citing works

Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands

HOROWITZ, M., Xi, Y., WILSON, K., & Kacena, M. A. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00030-7 · Cited by 215 · see citing works

Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor κB Ligand: Clinical Utility in Metabolic Bone Disease Assessment

Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215 · see citing works

Prostate Carcinoma Skeletal Metastases: Cross-talk between Tumor and Bone

Keller, E. T., Zhang, J., Cooper, C. R., Smith, P. C., McCauley, L. K., Pienta, K. J., & Taichman, R. S. (2001) · Cancer and Metastasis Reviews · doi:10.1023/a:1015599831232 · Cited by 197 · see citing works

Polymorphisms in the Osteoprotegerin Gene Are Associated With Osteoporotic Fractures

Langdahl, B. L., Carstens, M., Stenkjær, L. L., & Eriksen, E. F. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.7.1245 · Cited by 189 · see citing works

Increased frequency ofATM mutations in breast carcinoma patients with early onset disease and positive family history

Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R., & CONCANNON, P. J. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 111 · see citing works

Glucocorticoid-Induced Osteoporosis

Weinstein, R. S. (2001) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1010007108155 · Cited by 189 · see citing works

Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts

Prince, M., Banerjee, C., Javed, A., Green, J., Lian, J. B., Stein, G. S., Bodine, P. V. N., & Komm, B. S. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20010301)80:3 · Cited by 182 · see citing works

Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B

Weenig, R. H. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.12.006 · Cited by 181 · see citing works

The Role of Receptor Activator of Nuclear Factor- B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases

Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 175 · see citing works

Glucocorticoid-induced osteoporosis: who to treat with what agent?

Rizzoli, R., & Biver, E. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.188 · Cited by 166 · see citing works

Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor

Zannettino, A. C. W., Holding, C. A., Diamond, P., Atkins, G. J., Kostakis, P., Farrugia, A., Gamble, J. R., To, L. B., Findlay, D. M., & Haynes, D. R. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20354 · Cited by 166 · see citing works

Pathogenic mechanisms of glucocorticoid-induced osteoporosis

Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146 · see citing works

Root resorption and the OPG/RANKL/RANK system: a mini review

Tyrovola, J. B., Spyropoulos, M. N., Makou, M., & Perrea, D. N. (2008) · Journal of Oral Science · doi:10.2334/josnusd.50.367 · Cited by 142 · see citing works

Fibroblastic Stromal Cells Express Receptor Activator of NF-κB Ligand and Support Osteoclast Differentiation

Quinn, J. M. W., Horwood, N. J., Elliott, J., Gillespie, M. T., & Martin, T. J. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1459 · Cited by 141 · see citing works

Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKL

Hofbauer, L. C., Zeitz, U., Schoppet, M., Skalicky, M., Schüler, C., Stolina, M., Kostenuik, P. J., & Erben, R. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24445 · Cited by 133 · see citing works

Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis

Ueland, T., Bollerslev, J., Godang, K., Müller, F., Ss, F., & Aukrust, P. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450685 · Cited by 132 · see citing works

Serum osteoprotegerin levels in healthy controls and cancer patients.

Lipton, A., Ali, S. M., Leitzel, K., Chinchilli, V. M., Witters, L. M., Engle, L. L., Holloway, D. L., Bekker, P. J., & Dunstan, C. R. (2002) · PubMed · Cited by 132 · see citing works

Influence of Glucocorticoids on Human Osteoclast Generation and Activity

Sivagurunathan, S., Muir, M. M., Brennan‐Speranza, T. C., Seale, J. P., & Mason, R. S. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041233 · Cited by 125 · see citing works

Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis

Sasaki, N., Kusano, E., Ando, Y., Yano, K., Tsuda, E., & Asano, Y. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.3.479 · Cited by 123 · see citing works

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism

Hofbauer, L. C. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410195 · Cited by 120 · see citing works

Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice

Piemontese, M., Xiong, J., Fujiwara, Y., Thostenson, J. D., & O’Brien, C. A. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00219.2016 · Cited by 118 · see citing works

Glucocorticoid Regulation of Osteoclast Differentiation and Expression of Receptor Activator of Nuclear Factor-κB (NF-κB) Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvarial Bones

Swanson, C., Lorentzon, M., Conaway, H. H., & Lerner, U. H. (2006) · Endocrinology · doi:10.1210/en.2005-0717 · Cited by 114 · see citing works

Osteoclast formation and resorption

Lerner, U. H. (2000) · Matrix Biology · doi:10.1016/s0945-053x(00)00052-4 · Cited by 114 · see citing works

Regulation of Osteoprotegerin Secretion from Primary Cultures of Human Bone Marrow Stromal Cells

Brändström, H., Björkman, T., & Ljunggren, Ö. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4223 · Cited by 113 · see citing works

Disorders Associated With Acute Rapid and Severe Bone Loss

Epstein, S., Inzerillo, A. M., Caminis, J. N., & Zaidi, M. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2083 · Cited by 110 · see citing works

RANK-Fc: A therapeutic antagonist for RANK-L in myeloma

Sordillo, E. M., & Pearse, R. N. (2003) · Cancer · doi:10.1002/cncr.11134 · Cited by 109 · see citing works

Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.

Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107 · see citing works

Expression of Osteoprotegerin (Osteoclastogenesis Inhibitory Factor) in Cultures of Human Dental Mesenchymal Cells and Epithelial Cells

Sakata, M., Shiba, H., Komatsuzawa, H., Fujita, T., Ohta, K., Sugai, M., Suginaka, H., & Kurihara, H. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1486 · Cited by 103 · see citing works

Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-β by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts

詫摩, 敦., Kaneda, T., Sato, T., Ninomiya, S., Kumegawa, M., & Hakeda, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300213200 · Cited by 100 · see citing works

RANK, RANKL and osteoprotegerin in arthritic bone loss

Bezerra, M. C., de Carvalho, J. F., Prokopowitsch, A. S., & Pereira, R. M. R. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000200004 · Cited by 98 · see citing works

Effect of corticosteroids on human osteoclast formation and activity

HIRAYAMA, T., Sabokbar, A., & Athanasou, N. A. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750155 · Cited by 99 · see citing works

Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating facto

Chang, K., Chang, W. H.-S., Huang, S., Huang, S., & Shih, C. (2005) · Journal of Orthopaedic Research® · doi:10.1016/j.orthres.2005.03.012.1100230611 · Cited by 95 · see citing works

Estrogen receptor alpha, but not estrogen receptor beta, is involved in the regulation of the OPG/RANKL (osteoprotegerin/receptor activator of NF-kappa B ligand) ratio and serum interleukin-6 in male mice

Lindberg, M., Erlandsson, M. C., Alatalo, S., Windahl, S. H., Andersson, G. N., Halleen, J., Carlsten, H., Gustafsson, J., & Ohlsson, C. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1710425 · Cited by 91 · see citing works

RANKL and RANK as novel therapeutic targets for arthritis

Nakashima, T., & Penninger, J. M. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00016 · Cited by 89 · see citing works

Management of Glucocorticoid-Induced Osteoporosis

Rizzoli, R., Adachi, J. D., Cooper, C. C., Dere, W. H., Devogelaer, J. P., Díez‐Pérez, A., Kanis, J. А., Laslop, A., Mitlak, B., Papapoulos, S. E., et al. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9630-5 · Cited by 84 · see citing works

The relationship of denosumab pharmacology and osteonecrosis of the jaws

Malan, J., Ettinger, K. S., Naumann, E., & Beirne, O. R. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.08.439 · Cited by 83 · see citing works

Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene

Cheung, J., Mak, Y. T., Papaioannou, S., Evans, B. A., Fogelman, I., & Hampson, G. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770423 · Cited by 83 · see citing works

Reciprocal Control of Expression of mRNAs for Osteoclast Differentiation Factor and OPG in Osteogenic Stromal Cells by Genistein: Evidence for the Involvement of Topoisomerase II in Osteoclastogenesis

Yamagishi, T., Otsuka, E., & Hagiwara, H. (2001) · Endocrinology · doi:10.1210/en.142.8.3632 · Cited by 81 · see citing works

Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).

Buxton, E. C., Yao, W., & Lane, N. E. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032066 · Cited by 79 · see citing works

Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease

GARCÍA-VALDECASAS-CAMPELO, E., GONZÁLEZ-REIMERS, E., SANTOLARIA-FERNÁNDEZ, F., DE LA VEGA-PRIETO, M. J., MILENA-ABRIL, A., SÁNCHEZ-PÉREZ, M. J., MARTÍNEZ-RIERA, A., & GÓMEZ-RODRÍGUEZ, M. D. L. Á. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl004 · Cited by 77 · see citing works

Activated NF-κB in Bone Marrow Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients Inhibits Osteogenic Differentiation Through Downregulating Smad Signaling

Tang, Y., Xie, H., Chen, J., Geng, L., Chen, H., Li, X., Hou, Y., Lu, L., Shi, S., Zeng, X., et al. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0226 · Cited by 77 · see citing works

Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.

de Nijs, R. N. J. (2008) · PubMed · Cited by 74 · see citing works

Infliximab therapy for sarcoidosis (lupus pernio)

Haley, H. R., Cantrell, W., & Smith, K. (2004) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2004.05769.x · Cited by 75 · see citing works

Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density

Pineau, C. A., Urowitz, M. B., Fortin, P. R., Ibanez, D., & Gladman, D. D. (2004) · Lupus · doi:10.1191/0961203303lu1036oa · Cited by 74 · see citing works

Effect of glucocorticoids on bone density

Rehman, Q., & Lane, N. E. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10339 · Cited by 74 · see citing works

Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.

Fahrleitner, A., Prenner, G., Leb, G., Tscheliessnigg, K. H., Piswanger-Sölkner, C., Obermayer-Pietsch, B., Portugaller, H. R., Berghold, A., & Dobnig, H. (2003) · Bone · doi:10.1016/s8756-3282(02)00926-2 · Cited by 71 · see citing works

The effect of environmental cues on the differentiation of myofibroblasts in peritoneal granulation tissue

(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70 · see citing works

Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn’s disease.

von Tirpitz, C., Epp, S., Klaus, J., Mason, R., Hawa, G., Brinskelle-Schmal, N., Hofbauer, L. C., Adler, G., Kratzer, W., & Reinshagen, M. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200311000-00003 · Cited by 69 · see citing works

Osteoclasts—the innate immune cells of the bone

Wu, Y., Humphrey, M. B., & Nakamura, M. C. (2008) · Autoimmunity · doi:10.1080/08916930701693180 · Cited by 67 · see citing works

Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells

Kanzawa, M., Sugimoto, T., Kanatani, M., & Chihara, K. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420661 · Cited by 67 · see citing works

Potential mechanisms linking psychological stress to bone health

Ng, J.-S., & Chin, K.-Y. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.50680 · Cited by 66 · see citing works

Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages

Itonaga, I., Sabokbar, A., Murray, D. W., & Athanasou, N. A. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.1.26 · Cited by 66 · see citing works

Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis

Sasaki, N., Kusano, E., Ando, Y., Nemoto, J., Iimura, O., Ito, C., Takeda, S., Yano, K., Tsuda, E., & Asano, Y. (2002) · Bone · doi:10.1016/s8756-3282(02)00742-1 · Cited by 63 · see citing works

Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG)

Sasaki, N., Kusano, E., Takahashi, H., Ando, Y., Yano, K., Tsuda, E., & Asano, Y. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-004-0539-6 · Cited by 63 · see citing works

Cytokines and Bone Remodeling

Mundy, G. R., Oyajobi, B. O., Gutierrez, G. E., Sterling, J. A. R., Padalecki, S. S., Elefteriou, F., & Zhao, M. (2008) · Elsevier eBooks · doi:10.1016/b978-012370544-0.50020-3 · Cited by 59 · see citing works

Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease

Bernardi, S., Bossi, F., Toffoli, B., & Fabris, B. (2016) · BioMed Research International · doi:10.1155/2016/1752854 · Cited by 58 · see citing works

Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis

Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 57 · see citing works

Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity

Conaway, H. H., Henning, P., Lie, A., Tuckermann, J. P., & Lerner, U. H. (2016) · Bone · doi:10.1016/j.bone.2016.08.024 · Cited by 57 · see citing works

Bone Resorption in Chronic Otitis media: The Role of the Osteoclast

Jung, J. Y., & Chole, R. (2002) · ORL · doi:10.1159/000057787 · Cited by 58 · see citing works

1,25-Dihydroxyvitamin D3 and Prostaglandin E2 Act Directly on Circulating Human Osteoclast Precursors

Itonaga, I., Sabokbar, A., Neale, S. D., & Athanasou, N. A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1545 · Cited by 54 · see citing works

Pharmaceutical treatment of bone loss: From animal models and drug development to future treatment strategies

Brent, M. B. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108383 · Cited by 50 · see citing works

Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis

Haaber, J., Abildgaard, N., Knudsen, L. M., Dahl, I. M. S., Lodahl, M., Thomassen, M., Kerndrup, G. B., & Rasmussen, T. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06871.x · Cited by 49 · see citing works

Skeletal and extraskeletal actions of denosumab

Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 48 · see citing works

Glucocorticoid-Induced Osteoporosis: From Basic Mechanisms to Clinical Aspects

Alesci, S., Martino, M. U. D., Ilias, Ι., Gold, P. W., & Chrousos, G. P. (2005) · NeuroImmunoModulation · doi:10.1159/000082360 · Cited by 48 · see citing works

170th ENMC International Workshop: Bone protection for corticosteroid treated Duchenne muscular dystrophy. 27–29 November 2009, Naarden, The Netherlands

Quinlivan, R. C. M., Shaw, N., & Bushby, K. M. D. (2010) · Neuromuscular Disorders · doi:10.1016/j.nmd.2010.07.272 · Cited by 47 · see citing works

Low bone mineral density in adult patients with moderate to severe atopic dermatitis

Haeck, I. M., Hamdy, N. A. T., Mik, L. T.-D., Lentjes, E. G. W. M., Verhaar, H. J. J., Knol, M. J., de Bruin-Weller, M. S., & Bruijnzeel-Koomen, C. A. F. M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09327.x · Cited by 47 · see citing works

The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal models

Neumann, E., Gay, S., & Müller‐Ladner, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21361 · Cited by 45 · see citing works

Apoptotic molecular mechanisms implicated in autoimmune diseases.

Cacciapaglia, F., Spadaccio, C., Chello, M., Gigante, A., Coccia, R., Afeltra, A., & Amoroso, A. (2009) · PubMed · Cited by 46 · see citing works

Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins

Abrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 45 · see citing works

Osteogenic growth peptide effects on primary human osteoblast cultures: Potential relevance for the treatment of glucocorticoid‐induced osteoporosis

Spreafico, A., Frediani, B., Capperucci, C., Leonini, A., Gambera, D., Ferrata, P., Rosini, S., Stefano, A. D., Galeazzi, M., & Marcolongo, R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20836 · Cited by 41 · see citing works

Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation

Chen, C.-H., Chen, H.-A., Liao, H., Liu, C., Tsai, C., & Chou, C. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1543-y · Cited by 42 · see citing works

Nf1 limits epicardial derivative expansion by regulating epithelial to mesenchymal transition and proliferation

Baek, S. T., & Tallquist, M. D. (2012) · Development · doi:10.1242/dev.074054 · Cited by 39 · see citing works

Risk factors for osteoporosis in female patients with systemic lupus erythematosus

Munno, O. D., Mazzantini, M., Sedie, A. D., Mosca, M., & Bombardieri, S. (2004) · Lupus · doi:10.1191/0961203303lu1097oa · Cited by 40 · see citing works

RANK(L) as a Key Target for Controlling Bone Loss

Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8_9 · Cited by 37 · see citing works

A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass

Ibáñez, M., Ortiz, A. M., Castrejón, I., García-Vadillo, A., Carvajal, I., Castañeda, S., & González‐Álvaro, I. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2961 · Cited by 38 · see citing works

Glucocorticoid-induced osteoporosis

Kumar, R. (2001) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200109000-00007 · Cited by 37 · see citing works

Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption

Onyia, J. E., Galvin, R. J. S., Li, Y., Halladay, D., Miles, R. R., Yang, X., Fuson, T. R., Cain, R. L., Zeng, Q. Q., Chandrasekhar, S., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.057893 · Cited by 34 · see citing works

Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass

McCarty, M. F., Luján, L. M. L., & Assanga, S. B. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094776 · Cited by 34 · see citing works

Vitamin D and Osteoclastogenesis

Yasuda, H., Higashio, K., & Suda, T. (2005) · Elsevier eBooks · doi:10.1016/b978-012252687-9/50041-3 · Cited by 34 · see citing works

Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts

Jacobson, A., Johansson, S., Branting, M., & Melhus, H. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.092 · Cited by 34 · see citing works

Bone metabolism in patients more than five years after bone marrow transplantation

Kerschan‐Schindl, K., Mitterbauer, M., Füreder, W., Kudlacek, S., Grampp, S., Bieglmayer, C., Fialka‐Moser, V., Pietschmann, P., & Kalhs, P. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704618 · Cited by 34 · see citing works

Regulation of osteoprotegerin mRNA levels by dexamethasone in osteoblasts

Xiaota, W. (2002) · Chinese Journal of Osteoporosis

Printed in U.S.A. Copyright © 1999 by The Endocrine Society Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in

Osteoblastic, H., Cells, L., Paracrine, P., Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., & Spelsberg, T. C. (2013)

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1

Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works

Regulation of Osteoprotegerin mRNA Levels by Prostaglandin E2in Human Bone Marrow Stroma Cells

Brändström, H., Jonsson, K. B., Ohlsson, C., Vidal, O., Ljunghall, S., & Ljunggren, Ö. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8783 · Cited by 131 · see citing works

Thyroid hormones influence growth, differentiation and morphology of MC3T3E1 cells

Varga, F., Luegmayr, E., Rumpler, M., & Klaushofer, K. (1995) · Bone · doi:10.1016/8756-3282(95)90434-4 · Cited by 1 · see citing works